• KOLs Community
    • Malignant
    • Malignant Melanoma
    • Rona M M Mackie
    • RONA M M MacKie

      RONA M M MacKie

      Department of Medical Genetics, University of Glasgow, Glasgow, UK | Department of Public Health, University of Glasgow, Glasgow UK | Department of Medical Genetics, ...



      KOL Resume for RONA M M MacKie


      Department of Medical Genetics, University of Glasgow, Glasgow, UK


      Department of Medical Genetics, University of Glasgow, Glasgow G12 8QQ, UK;


      Department of Public Health and Health Policy, University of Glasgow, Glasgow, United Kingdom


      University of Glasgow, Glasgow, UK


      Public Health and Health Policy, University of Glasgow, UK


      University of Glasgow, Glasgow G12 8QQ, U.K


      Nottingham City Hospital, Nottingham, United Kingdom

      University of Glasgow, Glasgow

      Istituto Nazionale dei Tumori

      Charité, Benjamin Franklin Campus, Berlin, Germany

      and Institute Gustave Roussy, Villejuif Cedex, France.


      Alan Lyell Centre for Dermatology, Greater Glasgow and Clyde University NHS Trust, Glasgow, U.K.
*Department of Public Health and Health Policy, University of Glasgow, Glasgow G12 8RZ, U.K

      Department of Public Health and Health Policy, Faculty of Medicine, University of Glasgow, United Kingdom


      On behalf of the Scottish Melanoma Group

      Department of Dermatology, University of Glasgow, Glasgow, U.K.


      Department of Public Health and Health Policy, University of Glasgow, Glasgow G12 8RZ

      Duncan Guthrie Institute, Glasgow, UK


      Department of Dermatology, University of Glasgow, Glasgow, UK

      Duncan Guthrie Institute of Medical Genetics, Royal Hospital for Sick Children and University of Glasgow, Glasgow, U.K.


      Public Health and Health Policy University of Glasgow, Glasgow G12 8RZ, UK


      Department of Dermatology, Glasgow University, Glasgow, U.K

      Plastic Surgery Unit, Canniesburn Hospital, Glasgow, UK


      Department of Dermatology, University of Glasgow, G12 8QQ, UK

      Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, New South Wales, 2145, Australia


      Western Infirmary, Dumbarton Road, Glasgow


      Affiliations of authors: S. L. Harrison, Skin Cancer Research Group, School of Public Health and Tropical Medicine, James Cook University, Townsville, Australia; R. M. MacKie, Department of Dermatology, University of Glasgow, and the Royal Hospital for Sick Children, Glasgow, U.K.; R. MacLennan, Queensland Institute of Medical Research, Brisbane, Australia

      WHO Melanoma Programme:, Glasgow


      University Department of Dermatology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, United Kingdom

      Department of Dermatology, Western Infirmary, Glasgow, U.K.


      Department of Dermatology, University of Glasgow, Glasgow G12 8QQ, U.K.


      Department of Dermatology, Robertson Building, University of Glasgow, G12 8QQ, Glasgow, England


      University Departments of Dermatology, Western Infirmary, Glasgow, Scotland G11 6NT, UK

      Department of Vascular Surgery, Gartnavel General Hospital, 1053 Western Road, Glasgow G12 0YN U.K.


      Department of Dermatology, University of Glasgow, UK.

      Western General Hospital, Edinburgh, UK


      Department of Dermatology, University of Glasgow;, Glasgow G12 8QQ, U.K.

      University of Glasgow, Glasgow, UK, and University of Pennsylvania, Philadelphia, Pennsylvania, USA



      RONA M M MacKie: Influence Statistics

      Sample of concepts for which RONA M M MacKie is among the top experts in the world.
      Concept World rank
      labial melanotic #1
      chlorin topical treatment #1
      abnormal human epidermis #1
      200 basal cells #1
      randomization median followup #1
      management skin disease #1
      scotland guidelines #1
      preexisting naevus #1
      uva lamps risk #1
      maximum severities #1
      dermatitis infantile #1
      samples melana #1
      plantar surface leg #1
      pdgf melanoma #1
      quantification langerhans cell #1
      suitable protective eyewear #1
      lymphoid infiltrate evidence #1
      leu 8 lymphocytes #1
      actual predicted rate #1
      conditions average percentage #1
      white caucasian population #1
      keratosis phytohemagglutinins #1
      remission sequential estimation #1
      clinical diagnoses followup #1
      decade numbers #1
      histogenetic type #1
      interferongamma lymphocyte #1
      29 superficial #1
      proposed oncogenic potential #1
      families m53i mutations #1
      auto‐antibodies vitiligo #1
      thirtyseven infants #1
      rich lay vocabulary #1
      pulsed intranasal mupirocin #1
      expanded melanocytic #1
      role staphylococcal damage #1
      thirteen occasions #1
      melanoma 32 #1
      tbw schedule humans #1
      newborn publication dermatitis #1
      pagetoid reticulosis variant #1
      extrafacial lmm #1
      mutation exposed #1
      seborrheic diagnosis #1
      dermal lymphoid infiltrates #1
      patients plantar lesions #1
      65 positivity rate #1
      diverse screening campaigns #1
      fungal immunoglobulin #1
      fiftyeight pairs sunglasses #1


      Prominent publications by RONA M M MacKie

      KOL-Index: 17978

      BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability.

      METHODS: 1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627) 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of ...

      Known for Pegylated Interferon | Iii Melanoma | Adjuvant Therapy | Recurrencefree Survival | Resected Stage
      KOL-Index: 15344

      OBJECTIVE: To determine the changing incidence of and mortality from cutaneous malignant melanoma in Scotland from 1979 to 1994.

      DESIGN: Detailed registration of clinical and pathological features, surgical and other treatment, and follow up of all cases of cutaneous malignant melanoma diagnosed from 1979 to 1994 and registered with specialist database for Scotland.

      SETTING: Scotland.

      SUBJECTS: 6288 patients with invasive primary cutaneous malignant melanoma diagnosed between 1 January ...

      Known for Cutaneous Malignant Melanoma | Year Women | Incidence Survival | Thinner Tumours | Scotland 1979
      KOL-Index: 12558

      PURPOSE: Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL). Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) versus observation in patients with stage III melanoma.

      METHODS: A total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or ...

      Known for Adjuvant Therapy | Iii Melanoma | European Organisation | Life Hrqol | Pegylated Interferon
      KOL-Index: 12547

      BACKGROUND: The major factors individually reported to be associated with an increased frequency of CDKN2A mutations are increased number of patients with melanoma in a family, early age at melanoma diagnosis, and family members with multiple primary melanomas (MPM) or pancreatic cancer.

      METHODS: These four features were examined in 385 families with > or =3 patients with melanoma pooled by 17 GenoMEL groups, and these attributes were compared across continents.

      RESULTS: Overall, 39% of ...

      Known for Cdkn2a Mutations | Genomel Study | Melanoma Diagnosis | 40 Years | Pancreatic Cancer
      KOL-Index: 12482

      OBJECTIVE: To map potential sites of sex steroid action in the human vulva.

      METHODS: Monoclonal antibodies to androgen, oestrogen and progesterone receptors were used to stain frozen sections of vulval skin, vagina and suprapubic skin. A scoring system was devised to compare receptor distribution in the epidermis and dermis of skin with vaginal epithelium and stroma.

      RESULTS: Androgen receptors were seen in epidermal keratinocytes, sebaceous glands, sweat glands, hair follicles and ...

      Known for Progesterone Receptors | Vaginal Epithelium | Vagina Vulva | Immunohistochemical Study | Androgen Receptor
      KOL-Index: 12251

      BACKGROUND: Melanoma risk is related to sun exposure; we have investigated risk variation by tumour site and latitude.

      METHODS: We performed a pooled analysis of 15 case-control studies (5700 melanoma cases and 7216 controls), correlating patterns of sun exposure, sunburn and solar keratoses (three studies) with melanoma risk. Pooled odds ratios (pORs) and 95% Bayesian confidence intervals (CIs) were estimated using Bayesian unconditional polytomous logistic random-coefficients ...

      Known for Melanoma Risk | Sun Exposure | Head Neck | Body Sites | Low Latitudes
      KOL-Index: 12153

      Background: We report the experience of the World Health Organization (WHO) Melanoma Program concerning sentinel lymph node (SLN) biopsy for detecting patients with occult regional nodal metastases to submit to selective regional node dissection.Methods: From February 1994 to August 1998, in 12 centers of the WHO Melanoma Program, 892 SLN biopsies were performed in 829 patients with clinical stage I melanoma (male: 370; female: 459; median age: 50 years old). The location of the primary ...

      Known for Node Biopsy | Cutaneous Melanoma | Patients Sln | Sentinel Lymph | Child Female Humans
      KOL-Index: 12069

      BACKGROUND: Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 years. High-dose and low-dose interferon alfa have been assessed for the treatment of these patients, with the former having considerable toxicity and a consistent effect on disease free survival, but not on overall survival, and the latter no consistent effect on either. Our aim was, therefore, to assess the effect of two regimens of ...

      Known for Interferon Alfa | Iii Melanoma | Stage Iib | Intermediate Doses | Observation Patients
      KOL-Index: 11885

      BACKGROUND: The use of elective regional node dissection in patients with cutaneous melanoma without any clinical evidence of metastatic spread is still debated. Our aim was to evaluate the efficacy of immediate node dissection in patients with melanoma of the trunk and without clinical evidence of regional node and distant metastases.

      METHODS: An international multicentre randomised trial was carried out by the WHO Melanoma Programme from 1982 to 1989. The trial included only patients ...

      Known for Regional Nodes | Node Dissection | Randomised Trial | Patients Melanoma | Wide Excision
      KOL-Index: 11881

      A study of 953 invasive cutaneous malignant melanomas of the head and neck was performed to determine differences between lentigo maligna melanoma and other histogenetic types with regard to patients and sites affected; prognosis was analysed in 595 of these cases. The cases studied comprised all head and neck melanomas registered with the Scottish Melanoma Group between 1979 and 1992, apart from the 3% of cases that were unclassifiable or rare histogenetic types. The histogenetic types ...

      Known for Lentigo Maligna Melanoma | Histogenetic Type | Female Head | Tumour Thickness | Patients Lmm
      KOL-Index: 11190

      OBJECTIVE: To study incidence of and survival from cutaneous malignant melanoma in relation to socioeconomic status.

      DESIGN: Application of Carstairs deprivation score to all malignant melanoma patients diagnosed in a geographically defined area over a 15 year period.

      SETTING: West of Scotland (area population 2,716,900).

      SUBJECTS: 3142 patients first diagnosed with malignant melanoma in the period 1979-93.

      INTERVENTIONS: Surgical excision of primary malignant melanoma with additional ...

      Known for Socioeconomic Status | Malignant Melanoma | Incidence Cutaneous | Year Period | Skin Neoplasms
      KOL-Index: 10883

      BACKGROUND: There is a current need for a reliable prognostic marker for melanoma patients, particularly those with stage 2 and stage 3 disease, so that adjuvant therapies can be directed appropriately.

      OBJECTIVES: To establish whether or not the use of tyrosinase-specific or melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction (RT--PCR) of peripheral blood cells detects preclinical disease progression in patients with malignant melanoma.

      METHODS: Two hundred ...

      Known for Malignant Melanoma | Chain Reaction | Neoplasm Biomarkers | Reverse Transcriptase | Peripheral Blood Samples
      KOL-Index: 10427

      The efficacy and suitability of photodynamic therapy (PDT) was compared with that of cryotherapy in the treatment of 40 lesions of Bowen's disease. Lesions were randomized to receive either cryotherapy with liquid nitrogen, or PDT using a portable desktop lamp incorporating a 300 W xenon short arc discharge source. A porphyrin precursor, 5-aminolaevulinic acid (5-ALA), was applied topically 4 h before irradiation in the PDT group. Each lesion received 125 J/cm2 at a fluence rate of 70 ...

      Known for Cryotherapy Treatment | Photodynamic Therapy | Bowens Disease | Pdt Clearance | Lesions Bowen
      KOL-Index: 9434

      The incidence of cutaneous melanoma is rising rapidly in a number of countries. The key environmental risk factor is exposure to the ultraviolet (UV) component in sunlight. The nucleotide excision repair (NER) pathway deals with the main forms of UV-induced DNA damage. We have investigated the hypothesis that polymorphisms in NER genes constitute genetic susceptibility factors for melanoma. However, not all melanomas arise on sun-exposed sites and so we investigated the hypothesis that ...

      Known for Cutaneous Melanoma | Dna Repair | Genetic Predisposition | Ercc1 Xpf | Gene Polymorphisms

      Key People For Malignant Melanoma

      Top KOLs in the world
      Donald L Morton
      melanoma patients lymphatic mapping sentinel lymphadenectomy
      John Munn Kirkwood
      metastatic melanoma adjuvant therapy advisory consultancy
      Martin C Mihm
      malignant melanoma skin neoplasms clinical stage
      Arthur J Sober
      cutaneous melanoma clinical stage united states
      Charles M Balch†
      melanoma patients surgical oncology lymph node
      John F Thompson
      melanoma patients node biopsy sentinel lymph

      RONA M M MacKie:Expert Impact

      Concepts for whichRONA M M MacKiehas direct influence:Malignant melanoma,  Atopic dermatitis,  Cutaneous melanoma,  Cutaneous malignant melanoma,  Mycosis fungoides,  Skin neoplasms,  Retinoic acid,  Photodynamic therapy.

      RONA M M MacKie:KOL impact

      Concepts related to the work of other authors for whichfor which RONA M M MacKie has influence:Malignant melanoma,  Skin cancer,  Atopic dermatitis,  Photodynamic therapy,  Lymph node,  Sun exposure,  Mycosis fungoides.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Medical Genetics, University of Glasgow, Glasgow, UK | Department of Public Health, University of Glasgow, Glasgow UK | Department of Medical Genetics, University of Glasgow, Glasgow G12 8QQ, UK; | Department of Cancer Epidemiology, H.

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.